DERMIRA, INC. (NASDAQ:DERM) Files An 8-K Results of Operations and Financial Condition
Item2.02
|
Results of Operations and Financial Condition. |
On May8, 2017, Dermira,Inc. issued a press release announcing its
financial results for the quarter ended March31, 2017. The press
release is being furnished as Exhibit99.1.
| Item9.01 | Financial Statements and Exhibits. |
(d)Exhibits.
|
ExhibitNo. |
Description |
|
| 99.1 | Dermira Inc. Press Release dated May 8, 2017 |
The information furnished in this Current Report under Item 2.02
and the exhibit attached hereto shall not be deemed filed for
purposes of Section18 of the Securities Exchange Act of 1934, as
amended (the Exchange Act), or incorporated by reference in any
filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as shall be expressly set forth by specific
reference in such filing.
About DERMIRA, INC. (NASDAQ:DERM)
Dermira, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. The Company’s portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia (certolizumab pegol), DRM04 and DRM01. Cimzia is an injectable biologic tumor necrosis factor-alpha inhibitor, or TNF inhibitor, that is approved and marketed for the treatment of numerous inflammatory diseases spanning multiple medical specialties, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn’s disease. DRM04 is a topical, small-molecule anticholinergic product for the treatment of hyperhidrosis. DRM01 is a topical, small-molecule sebum inhibitor for the treatment of acne. DERMIRA, INC. (NASDAQ:DERM) Recent Trading Information
DERMIRA, INC. (NASDAQ:DERM) closed its last trading session down -0.22 at 31.74 with 187,474 shares trading hands.